Natural Disaster and Business Continuity Risks
First written in FY2016. 12 of 23 entries say "Mitigated", first in FY2017. Latest entry: FY2026.
The whole theme swung hardest in 2020: 22 of 111 companies on the "Worse" side.
- FY2026MitigatedAnnual report
「In preparation for natural disasters, pandemics and other events, the Group established the 共創未来グループ災害等対策委員会 to formulate and develop policies for responding to emergencies. Specifically, it has established a crisis-management framework, fully duplicated its core and peripheral systems, automated its logistics centres, installed private power generators and conducted regular drills.」
Regarding responses to natural disasters and pandemics, the company organised and strengthened its risk-management framework, including the disaster response committee, business continuity plans, full system duplication, private power generators and drills. - FY2025-H1MitigatedAnnual report
「The company entered into a strategic business alliance with Blue Innovation Co., Ltd., which develops and provides DX solutions using drones and robots, and began considering the establishment of a stable delivery system for pharmaceuticals and medical devices to disaster-stricken areas, remote locations and areas that are difficult to access during large-scale disasters.」
Regarding the delivery of pharmaceuticals and medical devices to remote areas and other locations during large-scale disasters, the company entered into a strategic business alliance with Blue Innovation Co., Ltd., which uses drones and robots, and began considering a stable delivery system. - FY2024MitigatedAnnual report
「In preparation for natural disasters, pandemics and other events, the Group has established a crisis-management framework, fully duplicated its core and peripheral systems, automated its logistics centres, installed private power generators and conducted regular drills. It has also identified the risks of natural disasters by area and prepared disaster response plans summarising the issues and countermeasures for each area.」
As specific measures for natural disasters and pandemics, the company has put in place private power generators, logistics-centre automation, regular drills and disaster response plans for each region. - FY2024-Q3WorsenedAnnual report
「In addition, although COVID-19 was reclassified as a Class 5 infectious disease and socioeconomic activity is returning to normal, the market outlook remains uncertain as influenza has spread earlier than usual and COVID-19 infections have expanded again.」
While socioeconomic activity is returning to normal, influenza has spread earlier than usual and COVID-19 infections have expanded again, and uncertainty in the market continues. - FY2024-Q2WorsenedAnnual report
「In addition, although COVID-19 was reclassified as a Class 5 infectious disease and socioeconomic activity is returning to normal, the market outlook remains uncertain as influenza has spread earlier than usual and COVID-19 infections have expanded again.」
While socioeconomic activity is returning to normal, influenza has spread earlier than usual and COVID-19 infections have expanded again, and uncertainty in the prescription pharmaceutical market continues. As the spread and renewed expansion have already occurred, the risks have materialised. - FY2024-Q1MitigatedAnnual report
「In addition, although COVID-19 was reclassified as a Class 5 infectious disease and socioeconomic activity is returning to normal, the market outlook remains uncertain because of concerns about the infection situation associated with increased opportunities to go out and its impact on the healthcare delivery system.」
Although the transition to Class 5 infectious disease status and the normalisation of socioeconomic activity eased some of the previous constraints, uncertainty remains regarding the infection situation and its impact on the healthcare delivery system. - FY2023-Q2WorsenedAnnual report
「The prescription pharmaceutical market in the six-month consolidated period continued to be affected by healthcare cost-containment measures, including a 6.69% reduction in the official drug price schedule on a drug-cost basis under the medical fee revision implemented in April 2022. However, the market posted positive growth as sales of related products, including treatments and testing kits, expanded amid a further spread of COVID-19 infections referred to as the seventh wave, in addition to growth in new and specialty pharmaceuticals, including cancer treatments.」
The company disclosed a further spread of COVID-19 referred to as the seventh wave, increasing uncertainty in the business environment due to the pandemic. Meanwhile, the market posted positive growth due to increased sales of related products. - FY2023-Q1RestatedAnnual report
「Meanwhile, although measures such as the easing of restrictions on activities indicate progress toward the normalisation of socioeconomic activity, concerns remain about the impact of a renewed spread of infection on the healthcare delivery system, and the market outlook remains uncertain.」
While activity is returning to normal through measures such as the easing of restrictions, the company continues to disclose uncertainty regarding the impact of renewed infections on the healthcare delivery system and the outlook. - FY2022MitigatedAnnual report
「The spread of COVID-19 has affected performance through restrictions on business activities and a decline in prescription volumes caused by patients’ reluctance to visit medical institutions due to concerns about infection risk. Although these effects are on a recovery trend, it remains difficult to make predictions at present, including when the infection will subside, and the Group’s business activities and performance may be significantly affected depending on the infection situation.」
Although the effects of patients’ reluctance to visit medical institutions and other factors were said to be on a recovery trend, the possibility of a continuing impact on performance depending on the infection situation remains. - FY2022-Q3WorsenedAnnual report
「Meanwhile, the emergence of new variants has raised concerns about the impact of a renewed spread of infection on the healthcare delivery system, and uncertainty about the outlook continues.」
While patients’ reluctance to visit medical institutions is improving, concerns remain about the renewed spread of infection due to new variants and its impact on the healthcare delivery system, and the outlook remains uncertain. - FY2022-Q2MitigatedAnnual report
「Patients’ reluctance to visit medical institutions was on a recovery trend, partly due to the widespread rollout of COVID-19 vaccinations, and the market posted positive growth.」
The company states that patients’ reluctance to visit medical institutions was on a recovery trend due to the widespread rollout of vaccinations and other factors, indicating some mitigation of the pandemic’s impact on demand. Meanwhile, the impact of the spread of infection on medical institutions continued. - FY2022-Q1WorsenedAnnual report
「Although patients’ reluctance to visit medical institutions due to concerns about COVID-19 infection is on a recovery trend, the market outlook remains uncertain because the number of infections has expanded again due to variant strains and other factors, and a state of emergency has been re-declared.」
While reluctance to visit medical institutions is on a recovery trend, infections have expanded again due to variant strains and other factors, and a state of emergency has been re-declared, leaving the business environment uncertain due to the pandemic. - FY2021-Q3MaterialisedAnnual report
「During the third quarter, the prescription pharmaceutical market continued to operate in a challenging environment due to the impact of the April 2020 drug price revision and healthcare cost-containment measures, including the promotion of generic drug use, as well as the renewed increase in patients refraining from seeking medical care because of concerns about infection risk amid the further spread of COVID-19, described as the third wave.」
The renewed expansion of patients’ reluctance to visit medical institutions caused by the third wave of COVID-19 is actually affecting the prescription pharmaceutical market and the business environment. - FY2021-Q2MaterialisedAnnual report
「During the second quarter, the prescription pharmaceutical market continued to operate in a challenging environment due to the impact of the April 2020 drug price revision and healthcare cost-containment measures, including the promotion of generic drug use, as well as the suspension of sales activities accompanying the spread of COVID-19 and patients refraining from seeking medical care due to concerns about the risk of infection.」
Restrictions on business activities and patients’ reluctance to visit medical institutions due to the spread of COVID-19 continue to manifest as a difficult environment for the prescription pharmaceutical market. - FY2021-Q1MaterialisedAnnual report
「However, due to patients’ reluctance to visit medical institutions because of concerns about COVID-19 infection and the suspension of business activities under the state of emergency, sales in the pharmaceutical wholesale business for the first quarter were ¥287,635 million, down 4.4% year on year, and segment profit (operating profit) was ¥2,155 million, down 35.2%.」
COVID-19-related reluctance to visit medical institutions and suspension of business activities actually affected the pharmaceutical wholesale business, resulting in a 4.4% decline in sales and a 35.2% decline in segment profit. - FY2020MaterialisedAnnual report
「In particular, regarding the impact of the spread of COVID-19, a decline in the number of prescriptions has recently been observed as patients refrain from visiting medical institutions due to concerns about infection risk. Sales and logistics functions may also be affected.」
Regarding natural disaster and pandemic risks, the company states that patients’ reluctance to visit medical institutions and the resulting decline in prescription volumes actually occurred in connection with COVID-19. - FY2019MitigatedAnnual report
「Recognising its public role as a healthcare and health-related company and its mission as social infrastructure, the company is reviewing each function from a business continuity perspective. It will pursue a safe and secure supply of pharmaceuticals by making the investments necessary to ensure stable supplies during earthquakes, pandemics and other events, based on the trust and support of its stakeholders.」
The company continues to review its functions from a business continuity perspective and proceed with investments, including measures for earthquakes and pandemics. - FY2019-Q3MitigatedAnnual report
「The company is building a comprehensive framework to further improve productivity by advancing the automation technologies developed to date, while fulfilling its social mission of ensuring stable pharmaceutical supplies even during disasters.」
The company is strengthening its distribution system, including stable pharmaceutical supplies during disasters, through the operation of TBC Hiroshima and the use of automation technologies. - FY2019-Q2MitigatedAnnual report
「The company is building a comprehensive framework to further improve productivity by advancing the automation technologies developed to date, while fulfilling its social mission of ensuring stable pharmaceutical supplies even during disasters.」
The company is strengthening its distribution system, including stable pharmaceutical supplies during disasters, through the operation of TBC Hiroshima and the use of automation technologies. - FY2018-Q3MitigatedAnnual report
「In November 2017, the company decided to construct an integrated logistics centre at Dynabase within the centrally located Keihin Truck Terminal in order to strengthen a safe and secure distribution system capable of supplying pharmaceuticals and other products stably even during disasters.」
The company reaffirmed its response of strengthening the system for stable supplies of pharmaceuticals and other products during disasters through the decision to construct an integrated logistics centre. - FY2018-Q2MitigatedAnnual report
「By constructing an integrated logistics centre within the Keihin Truck Terminal, located near a core wide-area disaster prevention base and designated by the Tokyo Metropolitan Government as a wide-area transport base for disasters, the company will strengthen its distribution system so that pharmaceuticals can be supplied stably even during disasters.」
The company is strengthening its distribution system to enable stable pharmaceutical supplies during disasters through the construction of an integrated logistics centre. - FY2017MitigatedAnnual report
「Recognising its public role as a healthcare and health-related company and its mission as social infrastructure, the company is reviewing each function from a business continuity perspective. It will pursue a safe and secure supply of pharmaceuticals by making the investments necessary to ensure stable supplies during earthquakes, pandemics and other events, based on the trust and support of its stakeholders.」
Regarding business continuity risks from natural disasters and other events, the company describes its response of reviewing functions and proceeding with investments, including measures for earthquakes and pandemics. - FY2016First statedAnnual report
「An unforeseen large-scale disaster may affect performance through lower sales, higher restoration costs and other factors.」
While the company has established a crisis-management framework and fully duplicated its core and peripheral systems, it identifies unforeseen large-scale disasters as a residual risk.